Tisotumab Vedotin - Latest Advances

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 15, 2025

Cost-effectiveness of chemotherapy for advanced and recurrent cervical cancer: a systematic review.

Journal: Frontiers in health services

Published: April 22, 2025

Recent advances in cervical cancer treatment: Innovations from early-stage to advanced disease.

Journal: Taiwanese journal of obstetrics & gynecology

Published: April 18, 2025

Rapidly progressive pneumonitis days after receiving tisotumab vedotin: a new antibody-drug conjugate.

Journal: BMJ case reports

Published: April 15, 2025

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of amivantamab plus lazertinib for non-small cell lung cancer, durvalumab for small cell lung cancer, tislelizumab for esophageal cancer, tisotumab vedotin for cervical cancer, ivosidenib for leukemia, and venetoclax for lymphoma in Japan.

Journal: International journal of clinical oncology

Published: April 11, 2025

Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies.

Journal: Chembiochem : a European journal of chemical biology

Published: April 11, 2025

Filters

Recent advances in antibody-drug conjugates for metastatic castration-resistant prostate cancer.

Recent advances in antibody-drug conjugates for metastatic castration-resistant prostate cancer.

Clinical pharmacologic considerations for antibody-drug conjugate in gynecologic cancers.

Clinical pharmacologic considerations for antibody-drug conjugate in gynecologic cancers.

Comprehensive Review of the Ocular Toxicities Associated With Antibody-Drug Conjugates Used to Treat Gynecological Cancers.

Comprehensive Review of the Ocular Toxicities Associated With Antibody-Drug Conjugates Used to Treat Gynecological Cancers.

Adverse event profiles of four monomethyl auristatin E-conjugated antibody drug conjugates: a disproportionality analysis based on the US FDA adverse event reporting system (FAERS) database.

Adverse event profiles of four monomethyl auristatin E-conjugated antibody drug conjugates: a disproportionality analysis based on the US FDA adverse event reporting system (FAERS) database.

Pharmacological characteristics of tisotumab vedotin (recombinant) (TIVDAK® 40 ‍mg Intravenous Solution) and clinical study results in recurrent or metastatic cervical cancer

Pharmacological characteristics of tisotumab vedotin (recombinant) (TIVDAK® 40 ‍mg Intravenous Solution) and clinical study results in recurrent or metastatic cervical cancer

Unlocking the potential of antibody-drug conjugates in cervical cancer: emerging targets and clinical trials.

Unlocking the potential of antibody-drug conjugates in cervical cancer: emerging targets and clinical trials.

Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody-drug conjugates: a narrative review.

Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody-drug conjugates: a narrative review.

Cost-effectiveness of chemotherapy for advanced and recurrent cervical cancer: a systematic review.

Cost-effectiveness of chemotherapy for advanced and recurrent cervical cancer: a systematic review.

Recent advances in cervical cancer treatment: Innovations from early-stage to advanced disease.

Recent advances in cervical cancer treatment: Innovations from early-stage to advanced disease.

Rapidly progressive pneumonitis days after receiving tisotumab vedotin: a new antibody-drug conjugate.

Rapidly progressive pneumonitis days after receiving tisotumab vedotin: a new antibody-drug conjugate.

Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies.

Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies.